Navigation Links
PLC Medical Systems Announces Publication of Care Study Update

FRANKLIN, Mass., July 16 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative cardiac and vascular medical device-based technologies, today announced that a follow-up study of the landmark Cardiac Angiography in Renally Impaired Patients (CARE) Study determined that Contrast-Induced Nephropathy (CIN) is associated with long-term adverse events, ranging from pulmonary edema to death, and that patients with CIN were twice as likely as those who did not develop CIN to experience adverse events.

The study was published in the June 25, 2009 issue of the Clinical Journal of the American Society of Nephrology (CJASN). This study, authored by Dr. Richard J. Solomon, Professor of Medicine, University of Vermont College of Medicine,, followed more than 70 percent of the original subjects of the CARE study. Dr. Solomon is a member of the Scientific Advisory Board for PLC Medical Systems, and is one of the principal investigators for PLC's FDA-approved pivotal trial for RenalGuard in the U.S.

Mark R. Tauscher, president and chief executive officer of PLC Systems, said, "CIN is a significant and growing concern worldwide, and the publication of this study adds scientific weight to the need to find a way of preventing it. We continue to be very encouraged by the work of scientists who are studying our RenalGuard System((R)), which we believe could be an effective solution in reducing the incidence rate of CIN."

Currently, RenalGuard((R)) is the subject of an investigator-sponsored trial to study its efficacy in mitigating against CIN at the University of Milan-Centro Cardiologico Monzino (CCM). This trial is designed to assess RenalGuard compared to standard overnight hydration, a prevalent method of treatment in the EU, in preventing CIN in patients undergoing cardiac catheterization procedures and percutaneous coronary interventions with baseline impairment in renal function.

PLC received the CE Mark Certificate for the RenalGuard System in December 2007 and concluded its pilot safety trial in the U.S. late in 2007. The company has received full approval from the FDA to commence a U.S. pivotal trial to study the effectiveness of RenalGuard in the prevention of CIN. In March 2008, PLC signed its first international distribution agreement for RenalGuard with Artech s.r.l., Cavezzo, Italy for distribution of its RenalGuard System in Italy, and in May 2009, PLC announced its second European distributor, IZASA Distribuciones Tecnicas S.A., headquartered in Barcelona, Spain, for the distribution of RenalGuard in Spain.

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina. PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, we may be unable to raise sufficient funds in the future to implement our business plan and/or commence our planned U.S. clinical trial for RenalGuard, the current clinical trial in Italy and the planned future U.S. clinical trial for RenalGuard as a safe and effective prevention device for contrast induced nephropathy may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2008, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC and CO2( )Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.

    Contact:  Mary T. Conway
    Conway Communications

SOURCE PLC Systems Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. In Colorado, Commercial Medical and Pharmacy Benefit Enrollment Down at State Level
2. Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio
3. "Aprima Medical Software, Inc.," Unveiled by iMedica; Premier EHR / PM Company Adopts New Name
4. Tube Feeding Error: Fatal Medical Mistakes
5. Aprima Medical Software, Inc., Unveiled by iMedica; Premier EHR / PM Company Adopts New Name
6. Demand for Short-Term Medical Help Leads to Growth for Travel Nursing Staffing Agency; Prompts Move to New Location and Addition of New Online Tools for Nurses
7. Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit
8. Bronx Jury Awards 60 Million Dollars to Woman in Medical Malpractice Case
9. MultiNational Underwriters Is Now HCC Medical Insurance Services
10. Marathon Health Adds Fitness Center Capability -- Medically-based Fitness Centers Show Improved Engagement and Efficacy
11. MedicAlert Foundation and Autism Society Launch New Program to Safeguard Individuals and Families Living With Autism
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are ... for this recognition are considered among the top 2 percent of lawyers practicing within ... of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 If ... Leaders Scholarship is any indication, the future is in ... at by the Diabetes Scholars Foundation ... the way of academic and community service excellence. ... since 2012, and continues to advocate for people with ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: